|
Post by savzak on Dec 12, 2014 8:38:42 GMT -5
|
|
|
Post by otherottawaguy on Dec 12, 2014 9:18:44 GMT -5
Is it possible to cut and paste the articles here along with the link. It keeps us from giving these guys anymore clicks than their garbage deserves. We all want to read it to see what kind of crap they are spewing I just don't think we should be supporting their endeavours. Nothing of significance since the last CRL (except the dilution) has been ever true, why support it.
OOG
|
|
|
Post by savzak on Dec 12, 2014 9:22:13 GMT -5
Is it possible to cut and paste the articles here along with the link. It keeps us from giving these guys anymore clicks than their garbage deserves. We all want to read it to see what kind of crap they are spewing I just don't think we should be supporting their endeavours. Nothing of significance since the last CRL (except the dilution) has been ever true, why support it.
OOG Here you go:
Is MannKind Corporation in Bed With Crooks? And Should Investors Care?
By Brian Orelli | More Articles | Save For Later December 12, 2014 | Comments (0)
MannKind's (NASDAQ: MNKD ) marketing partner Sanofi (NYSE: SNY ) might be in big trouble. In a lawsuit filed last week, a former Sanofi employee claims she was fired after resisting the approval of nine contracts with consulting firms worth $34 million, because she believed the money was destined to be used for kickbacks to doctors and pharmacists to prescribe Sanofi's diabetes drugs.
Should investors be concerned? Let's take a closer look.
The lawsuit claims the illegal scheme goes all the way to the top of the pyramid, with former CEO Christopher Viehbacher involved. Viehbacher was fired in October, but the board didn't give a reason for removing its CEO. Although, there was a hint in the press release that Viehbacher wasn't working closely enough with his board: "Going forward, the Group needs to pursue its development with a management aligning the teams, harnessing talents and focusing on execution with a close and confident cooperation with the Board."
Source: MannKind.
Sanofi is MannKind's new marketing partner on its inhaled insulin drug Afrezza, so if Sanofi has done something illegal -- and that certainly hasn't been proved yet -- then MannKind technically would be in bed with crooks. But it remains a "maybe" at this point, since it hasn't been proved in court, nor has Sanofi admitted any wrongdoing.
Unfortunately, this kind of thing happens far too often in the pharmaceutical industry. In fact, Sanofi settled a lawsuit by the Department of Justice and several states a few years ago that claimed doctors were given free samples of an arthritis medication, Hyalgan, as a way to encourage them to prescribe the drug.
While giving out free samples is legal for patients covered under private insurance, patients covered under Medicare and Medicaid can't receive discounts because the government is worried that it'll encourage writing of prescriptions for drugs that the patient doesn't need.
And because Hyalgan is administered by the doctor, the free samples resulted in a lower average price that the doctors had to pay for the medication, but government insurance plans reimbursed at the full sale price.
Sanofi had to pay $109 million to settle the lawsuit. It's hard to know for sure, but it wouldn't surprise me if the French company made more than that off the scheme.
Afrezza isn't even due to launch until next year, so MannKind isn't in any way associated with the current lawsuit. And I doubt any settlement that might come about would cause Sanofi to be unable to sell Afrezza.
You could argue that Sanofi's name might be tainted, making it harder to market Afrezza to doctors, but of all the things investors need to worry about, I think that ranks pretty low. Investors should be much more concerned about whether doctors will prescribe Afrezza, especially given the lung warnings on the label, and whether insurers will pay for the drug.
|
|
|
Post by otherottawaguy on Dec 12, 2014 9:27:50 GMT -5
Like the above post by Savzak but only if haven't gone to read the article on Motley Fool
Like this post if you went to Motley Fool and read the article.
We can see the effect of how many are reading and where.
Thanks,
OOG
|
|
|
Post by bighaus89 on Dec 12, 2014 12:17:55 GMT -5
My post from YMB:
It seems as though hit pieces are really reaching for things to spin negatively. The recent article from Brian Orelli aka B.O. demonstrates just that. I think at this point, people that have done their DD are riding the storm in anticipation of sales beginning early next year. Shorts have already turned the weak longs upside down and shaken the pennies out of their pockets.
|
|
|
Post by beardawg on Dec 12, 2014 19:43:31 GMT -5
OOG,
I clicked before I saw the pasted article. I should have known better; I see the article pasted after the link all the time.
|
|
|
Post by doodyfree on Dec 12, 2014 23:23:36 GMT -5
Hey guys, I signed up for morning-star premium, and got access to their MNKD eval. what's your opinion on the 35% of 2B revenue, and 6.5 pps valuation?
Valuation 11/03/2014 We maintain our fair value estimate of $6.50 per share and view Afrezza's prospects more favorably now that Mannkind has secured Sanofi as a commercialization partner. Our projections assume Afrezza could generate more than $2 billion in peak sales, given the expansive and rapidly growing diabetes market, although MannKind will only see a portion of these sales based on its 35% profit share agreement with Sanofi. We assume that Afrezza launches in 2015 in the U.S. and slowly begins ramping up sales and milestone payments for MannKind, as Sanofi drives sales and gains regulatory approvals in other key markets such as the E.U. and Japan.
|
|
|
Post by jpg on Dec 13, 2014 0:29:44 GMT -5
Hey guys, I signed up for morning-star premium, and got access to their MNKD eval. what's your opinion on the 35% of 2B revenue, and 6.5 pps valuation? Valuation 11/03/2014 We maintain our fair value estimate of $6.50 per share and view Afrezza's prospects more favorably now that Mannkind has secured Sanofi as a commercialization partner. Our projections assume Afrezza could generate more than $2 billion in peak sales, given the expansive and rapidly growing diabetes market, although MannKind will only see a portion of these sales based on its 35% profit share agreement with Sanofi. We assume that Afrezza launches in 2015 in the U.S. and slowly begins ramping up sales and milestone payments for MannKind, as Sanofi drives sales and gains regulatory approvals in other key markets such as the E.U. and Japan. Hi DF, The Morningstar opinion is one of many many opinions. It think it fits in the 'lower middle ground' of many other opinions. The price per share quoted reflects the price derived from modelling peak sales with a risk and time premium for that opinion. No more no less. If I believed that opinion I would invest elsewhere. The beauty of markets is that we know only after the fact which opinion was right! We shall soon find out. JPG PS: as a long time contrarian I kind of like it when longs start sounding as if they are capitulating...
|
|
|
Post by doodyfree on Dec 13, 2014 3:14:45 GMT -5
I agree, I think they're low-balling the revenue and valuation. By peak-sale we should be much higher, and there should be other products/sources of revenue down the pipe. (Or we would have already been bought)
Another interesting observation is they recommend to considering selling only at $11+
Their analysis was also very bullish! Exactly how I believe it will be marketed, and why it will be successful.
MannKind and new global commercialization partner Sanofi will position MannKind's Afrezza as a differentiated diabetes therapy that offers safety and efficacy superior to injectable rapid-acting insulin. As an ultra-rapid-acting mealtime insulin, Afrezza may allow for superior disease management to injectable insulin. Currently available insulin products are characterized by slow onset and slow offset of activity, as they must be absorbed by the skin and then broken down by the body. In contrast, Afrezza delivers insulin monomers directly into the bloodstream via inhalation into the deep lung and thus more closely matches the body's natural physiological response to increases in blood sugar. Accordingly, Afrezza has been shown to achieve comparable levels of overall glucose control as seen with current state-of-the-art insulins, while demonstrating a lower risk of hypoglycemia and weight gain.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 13, 2014 7:27:06 GMT -5
I don't think they're matching their PT to peak sales, they are different pieces of their opinion. At 2 billion peak sales there is noway the stock price would be $6.50. That would put their p/e under 10!
|
|
|
Post by savzak on Dec 13, 2014 9:50:42 GMT -5
|
|
|
Post by jpg on Dec 13, 2014 12:59:43 GMT -5
It saves on the typing and thinking. After a while it's hard to come up with garbage to trow at Mannkind. At least a year ago I read someone who laid out the short game plan as we moved towards commercialization. It's interesting to see to what extent it has been followed. Every argument used (except dilution) has been proven wrong but guys like Orelli just disregard are their wrong predictions and move on to the next paper tiger argument. Eventually those will prove to be wrong also but by then the Orelli of the world will simply move on to the next contract. I wonder how much they get for these poorly researched hit pieces? They can't be in it for the few pennies a click? Then again it takes so little time to write the type of articles Orelli writes that he might be well paid for the little time it takes him to write these things. JPG
|
|
|
Post by savzak on Dec 13, 2014 15:08:36 GMT -5
More slightly modified and reported FUD based on Orelli's garbage. The title if this one is way over the top. "Crooks Inside Mannkind Corporation" even though they're still just talking about Sanofi. When it gets this sloppy and desperate, it's makes sense to wonder if the end is near. Maybe we turn around after the holidays and the end of tax selling. www.wallstreet.org/2014/12/crooks-inside-mannkind-corporationnasdaqmnkd/146622.htmlCrooks Inside MannKind Corporation(NASDAQ:MNKD) News4 hours ago Sanofi (NYSE:SNY) the marketing partners of MannKind (NASDAQ:MNKD) could be in real trouble. A former Sanofi employee filed a suit last week that she got fired because she resistedapproval of nine contracts with their consulting firms worth $34 million and that she believed this was given to pharmacists and doctors for kickbacks to prescribe their diabetes drugs. Should the Investors Care about this? Let’s look at some facts. According to the lawsuit, the top level of management Sanofi (NYSE:SNY) is also involved in this illegal scheme, including the CEO Christopher Viebbacher. The Board never gave any reasons for firing the CEO Christopher Viebbacher in October. But there was just a hint that Viebbacher was not working well enough with the board. For group to move forward, it needs to align the teams with the management to pursue their development, growing talents and focus on their execution along with the confident and close cooperation with Board. MannKind Corporation (NASDAQ:MNKD) is in partnership with Sanofi (NYSE:SNY) for the marketing of its Afrezza inhaling insulin drug. If Sanofi(NYSE:SNY)is involved in something illegal,Mannkind (NASDAQ:MNKD)must have crooks inside their business, although it is not yet proved. But still it’s a big speculation at this stage and also, court has not given any rulings in to the matter as yet. Unfortunately, in pharmaceutical industry, this kind of situations arises many times. Sanofi (NYSE:SNY) a few years ago settled a lawsuit with several states and Department of Justice that the doctors were given Hyalgan, an arthritis medications as a free sample just to encourage them to prescribe this drug to patients. While patients covered under the private insurance are allowed to be given free samples, patients who are covered under the Medicaid and Medicare cannot be given free sample because the government feels this will encourage the prescription of those drugs that patient don’t need. The Hyalgan is to be used under administration of the doctor and free samples showed the doctor had to pay lower average price for the medication and on the other hand because of the government insurance plan they are reimbursed on the full sale price. For the settlement of the lawsuit, Sanofi (NYSE:SNY) had to pay $109 million. It is hard to say at the moment if the company was involved in any illegal practice, however, if it did; it must have made much more than the amount it paid to settle the lawsuit. The launch of Afrezza is not due until the next year, so this makes MannKind (NASDAQ:MNKD) in no connection with this current lawsuit.There are doubts that Sanofi (NYSE:SNY)’s settlement will effects the selling of Afrezza in any way. One can argue that the Sanofi (NYSE:SNY)’s name might affect that marketing of Afrezza, but should the investor worry. Possibility for that happening is very low. In fact, the investors should be concerned that whether Afrezza will succeed in becoming the ultimate treatment solution or will it be just another drug on the shelf.
|
|
|
Post by jpg on Dec 13, 2014 19:15:22 GMT -5
I'm not a lawyer but that kind of title seems to be libel. Not that MNKD will (or should) do anything about this trash obviously but any source putting out these type of headlines lacks a credible editorial mechanism. These publications aren't worth the electrons they are printed on. Orelli and MFool are selling the little credibility they has. I used to think MF wasn't in on it but this now seems unlikely.
JPG
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 13, 2014 20:23:48 GMT -5
In my opinion, this latest slant should have MNKD fired up, have their lawyers making calls, and have longs uniting together to let the authors what we think.
"Crooks Inside Mannkind".
How ridiculous. Interestingly enough if you can manage to get thru the title, the rest of it reads like a foreign 3rd grader just learning tenses of the English language.
|
|